Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx (Nasdaq: CDNA) announced on October 22, 2025 the appointment of Suresh Gunasekaran to its Board of Directors.
Gunasekaran is president and CEO of UCSF Health, which the release notes has over $9 billion in annual revenue and 20,000 employees. He brings more than 20 years of executive leadership in healthcare administration and information technology and prior CEO and senior roles at University of Iowa Hospitals & Clinics, UT Southwestern, Healthlink/IBM, Gartner, and Vanderbilt Children’s Hospital.
CareDx highlighted Gunasekaran’s experience in clinical innovation and health system leadership and said his perspective will support the company’s efforts to advance diagnostic solutions for transplant patients.
CareDx (Nasdaq: CDNA) will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025. The company will host a webcast and conference call the same day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. Telephone participants must register to receive a dial-in number and unique PIN.
CareDx (Nasdaq: CDNA) announced product launches and regulatory milestones at ASHI 2025 (Oct 6–10, 2025) highlighting new HLA diagnostics and European IVDR certification. Key items include the AlloSeq Tx11 launch with enhanced Class II coverage plus non‑HLA markers (ABO, CCR5, LIMS1, APOL1); a modernized SCORE 7 analysis app for QTYPE; a novel same‑day long‑read HLA assay offered via an Early Access Program; and an ABO genotyping qPCR assay that showed 100% concordance with established methods across three clinical sites. CareDx said its AlloSeq Tx and QTYPE products received IVDR certification in the EU, meeting the new regulatory standard ahead of the December 2027 deadline.
CareDx (NASDAQ:CDNA), a precision medicine company focused on transplant healthcare solutions, has submitted its comment letter responding to the draft Local Coverage Determination (LCD) regarding molecular testing for solid organ transplant rejection. The comment letter is available on the company's website, following the conclusion of the public comment period on August 31, 2025. A final LCD and stakeholder comment summary are expected to be published by CMS.
CareDx (NASDAQ:CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The company will engage in a fireside chat presentation on September 5, 2025, at 8:00 AM ET in Boston, Massachusetts.
Investors and interested parties can access both the live and archived versions of the presentation through the "Events and Presentations" section on CareDx's investor relations website at investors.caredx.com.
CareDx (NASDAQ:CDNA), a precision medicine company focused on transplant healthcare solutions, has appointed Nathan Smith as its new Chief Financial Officer. Smith brings over 14 years of experience in molecular diagnostics, including senior finance roles at Myriad Genetics and CFO positions at Blackrock Neurotech and WIN Brands.
The appointment comes as current CFO Abhishek Jain announces his retirement, though he will continue supporting the company in a consulting capacity to ensure a smooth transition. CEO John Hanna emphasized Smith's operational excellence and experience in scaling diagnostics companies efficiently as key factors for the company's next growth phase.
CareDx (NASDAQ:CDNA) reported Q2 2025 financial results with mixed performance. The company achieved adjusted revenue of $90.5 million, up 14% year-over-year, while testing services volume grew 13% to 49,500 tests. AlloSure Kidney testing volumes showed strong growth of nearly 20% year-over-year.
The company reported a GAAP net loss of $8.6 million ($0.16 per share) but achieved non-GAAP net income of $5.6 million ($0.10 per share). CareDx maintains a strong balance sheet with $186 million in cash after completing a $50 million share repurchase. The company narrowed its full-year 2025 revenue guidance to $367-373 million and maintained adjusted EBITDA guidance of $29-33 million.
Notable business achievements include the publication of the KOAR manuscript, launch of AlloSure Plus AI-driven diagnostic platform, and successful EPIC environment installation.
CareDx (NASDAQ: CDNA) has published its landmark Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation, demonstrating the clinical utility of its AlloSure® donor-derived cell-free DNA (dd-cfDNA) test in kidney transplant surveillance.
The extensive study, involving 1,743 patients across 56 U.S. transplant centers and 18,584 AlloSure tests, revealed that elevated AlloSure was associated with a 6-fold increase in rejection detection in surveillance biopsies and a 4-fold increase in for-cause biopsies. The test can detect rejection up to four months before antibody-mediated rejection (ABMR) and one month before T-cell mediated rejection (TCMR), positioning it as a powerful early detection tool in kidney transplantation.
CareDx (NASDAQ:CDNA) announced significant advancements in AI-powered transplant diagnostics at the 2025 World Transplant Congress, featuring over 40 abstracts and 16 oral presentations. The company unveiled AlloSure® Plus, an AI-driven diagnostic platform integrated with EPIC Aura, validated through 2,700+ renal transplant biopsies by the Paris Transplant Group.
Key research findings include: an 8.166-fold increased risk of graft loss in kidney transplant recipients with elevated dd-cfDNA, successful monitoring of hard-to-place kidney transplants, and nearly doubled risk of complications in heart transplant recipients with elevated biomarkers. The company will host a symposium on August 4, 2025, focusing on precision molecular intelligence in transplant management.
CareDx (NASDAQ:CDNA), a company specializing in transplant healthcare solutions, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers 1-800-274-8461 (domestic) or 1-203-518-9814 (international) with Conference ID: CareDx, or through the webcast available on the company's investor relations website.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
